Literature DB >> 8178822

The rates of G:C-->T:A and G:C-->C:G transversions at CpG dinucleotides in the human factor IX gene.

R P Ketterling1, E Vielhaber, S S Sommer.   

Abstract

We have identified eight independent transversions at CpG in 290 consecutive families with hemophilia B. These eight transversions account for 16.3% of all independent transversions in our sample, yet the expected frequency of CpG transversions at random in the factor IX gene is only 2.6% (P < .01). The aggregate data suggest that the two types of CpG transversions (G:C-->T:A and G:C-->C:G) possess similar mutation rates (24.8 x 10(-10) and 20.6 x 10(-10), respectively), which are about fivefold greater than the comparable rates for transversions at non-CpG dinucleotides. The enhancement of transversions at CpG suggests that the model by which mutations occur at CpG may need to be reevaluated. The relationship, if any, between deamination of 5-methyl cytosine and enhancement of transversions at CpG remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8178822      PMCID: PMC1918263     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  22 in total

1.  Genomic amplification with transcript sequencing.

Authors:  E S Stoflet; D D Koeberl; G Sarkar; S S Sommer
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

2.  Nucleotide sequence of the gene for human factor IX (antihemophilic factor B).

Authors:  S Yoshitake; B G Schach; D C Foster; E W Davie; K Kurachi
Journal:  Biochemistry       Date:  1985-07-02       Impact factor: 3.162

3.  In vitro correction of G.T mispairs to G.C pairs in nuclear extracts from human cells.

Authors:  K Wiebauer; J Jiricny
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

4.  Molecular basis of base substitution hotspots in Escherichia coli.

Authors:  C Coulondre; J H Miller; P J Farabaugh; W Gilbert
Journal:  Nature       Date:  1978-08-24       Impact factor: 49.962

Review 5.  Spontaneous mutation in man.

Authors:  F Vogel; R Rathenberg
Journal:  Adv Hum Genet       Date:  1975

6.  A specific mismatch repair event protects mammalian cells from loss of 5-methylcytosine.

Authors:  T C Brown; J Jiricny
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

7.  Gene deletions in patients with haemophilia B and anti-factor IX antibodies.

Authors:  F Giannelli; K H Choo; D J Rees; Y Boyd; C R Rizza; G G Brownlee
Journal:  Nature       Date:  1983 May 12-18       Impact factor: 49.962

8.  Parameters affecting the yield of DNA from human blood.

Authors:  S Gustafson; J A Proper; E J Bowie; S S Sommer
Journal:  Anal Biochem       Date:  1987-09       Impact factor: 3.365

9.  Cytosine methylation and the fate of CpG dinucleotides in vertebrate genomes.

Authors:  D N Cooper; M Krawczak
Journal:  Hum Genet       Date:  1989-09       Impact factor: 4.132

10.  The Pennsylvania hemophilia program 1973-1978.

Authors:  M E Eyster; J H Lewis; S S Shapiro; F Gill; M Kajani; D Prager; I Djerassi; S Rice; C Lusch; A Keller
Journal:  Am J Hematol       Date:  1980       Impact factor: 10.047

View more
  11 in total

1.  Estimation of DNA sequence context-dependent mutation rates using primate genomic sequences.

Authors:  Wei Zhang; Gerard G Bouffard; Susan S Wallace; Jeffrey P Bond
Journal:  J Mol Evol       Date:  2007-08-04       Impact factor: 2.395

2.  Methods for incorporating the hypermutability of CpG dinucleotides in detecting natural selection operating at the amino acid sequence level.

Authors:  Yoshiyuki Suzuki; Takashi Gojobori; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2009-07-06       Impact factor: 16.240

Review 3.  The lacI gene as a target for mutation in transgenic rodents and Escherichia coli.

Authors:  J G de Boer; B W Glickman
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

4.  Haemophilia B: database of point mutations and short additions and deletions, 7th edition.

Authors:  F Giannelli; P M Green; S S Sommer; M C Poon; M Ludwig; R Schwaab; P H Reitsma; M Goossens; A Yoshioka; M S Figueiredo; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1997-01-01       Impact factor: 16.971

5.  Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations.

Authors:  Alessio Branchini; Mattia Ferrarese; Matteo Campioni; Giancarlo Castaman; Rosella Mari; Francesco Bernardi; Mirko Pinotti
Journal:  Blood       Date:  2017-02-14       Impact factor: 22.113

6.  Mutation rates in humans. I. Overall and sex-specific rates obtained from a population study of hemophilia B.

Authors:  P M Green; S Saad; C M Lewis; F Giannelli
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

7.  Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways.

Authors:  D W Benson; G M Silberbach; A Kavanaugh-McHugh; C Cottrill; Y Zhang; S Riggs; O Smalls; M C Johnson; M S Watson; J G Seidman; C E Seidman; J Plowden; J D Kugler
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

8.  Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII.

Authors:  R Vervoort; M R Islam; W S Sly; M T Zabot; W J Kleijer; A Chabas; A Fensom; E P Young; I Liebaers; W Lissens
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

9.  Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994.

Authors:  F Giannelli; P M Green; S S Sommer; D P Lillicrap; M Ludwig; R Schwaab; P H Reitsma; M Goossens; A Yoshioka; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1994-09       Impact factor: 16.971

10.  Haemophilia B (sixth edition): a database of point mutations and short additions and deletions.

Authors:  F Giannelli; P M Green; S S Sommer; M C Poon; M Ludwig; R Schwaab; P H Reitsma; M Goossens; A Yoshioka; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.